Genfit (NASDAQ:GNFT) Trading Up 1.2%

Genfit S.A. (NASDAQ:GNFT) was up 1.2% during mid-day trading on Friday . The stock traded as high as $3.49 and last traded at $3.49. Approximately 1,426 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 14,712 shares. The stock had previously closed at $3.45.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Genfit in a research note on Friday, April 5th.

Genfit Stock Performance

The firm’s 50 day moving average price is $3.57 and its 200-day moving average price is $3.53. The company has a quick ratio of 2.94, a current ratio of 2.94 and a debt-to-equity ratio of 0.92.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. boosted its stake in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 82,359 shares of the company’s stock after purchasing an additional 78,823 shares during the period. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 at the end of the most recent reporting period. Institutional investors own 2.24% of the company’s stock.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.